Stocktoria
NOVAVAX INC NVAX
NOVAVAX INC (NVAX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.1B at a 39.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.441 |
| Retained earnings / assets | -3.883 |
| EBIT / assets | 0.385 |
| Equity / liabilities | -0.098 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NVAX | NOVAVAX INC | 4/9 | -7.28 | 3.3 | +64.7% |
| TECH | BIO-TECHNE Corp | 5/9 | 5.89 | 151.4 | +5.2% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
| RGEN | REPLIGEN CORP | 6/9 | 5.48 | 169.6 | +16.4% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
About NOVAVAX INC
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
FAQ
Is NVAX financially healthy?
NOVAVAX INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NVAX pay a dividend?
No, NOVAVAX INC does not currently pay a dividend.
How profitable is NVAX?
In FY2025, NOVAVAX INC had a net margin of 39.2%.
What is NVAX's P/E ratio?
NOVAVAX INC's trailing price-to-earnings (P/E) ratio is about 3.3×, based on its latest annual earnings.
What is the analyst price target for NVAX?
The average Wall-Street price target for NOVAVAX INC is $14.11, about 77.3% above the recent price, from 9 analysts (consensus: buy).
Is NVAX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NOVAVAX INC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 3.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.